Healthcare Services company Vijaya Diagnostic Centre announced Q1FY26 results Revenue from Operations: Rs 1,880.5 million, up 20.4% YoY from Rs 1,562.2 million EBITDA: Rs 735.3 million, a 20.1% YoY increase from Rs 612.4 million EBITDA Margin: 39.1%, down 10 bps from 39.2% Profit After Tax (PAT): Rs 383.4 million, up 3.5% YoY from Rs 313.5 million PAT Margin: 20.4%, up 32 bps from 20.1% Commenting on the Business Outlook, Suprita Reddy, MD & CEO said “Vijaya reported another strong financial quarter, achieving a YOY growth of 20.4%, with our Hyderabad market’s contribution returning to double-digit growth this quarter. The strong performance was largely driven by volume and change in the test mix. I'm happy to state that all the new hubs in Pune, Bengaluru, and West Bengal are up and running, with steady footfall. We remain optimistic about achieving break-even across all centres within the 12 months with 1 hub centre in Bengaluru on track to reach break-even earlier than the estimated timeline. I’m also pleased to share that our Nizamabad hub centre has achieved break-even within 2 quarters of its full-fledged operations. Looking ahead, we would be commissioning 3 hubs in Q2 FY26 across our Core Geography and West Bengal. The other 2 hubs in West Bengal are also on track to be operationalized in 2nd half of FY26.” Result PDF
Green & Renewable Energy company ACME Solar Holdings announced Q1FY26 results Total Revenue grew by 71.8%, from Rs 340 crore to Rs 584 crore EBITDA increased by 75.7%, from Rs 302 crore to Rs 531 crore EBITDA Margin improved to 90.9%, up from 88.8% PAT surged by 9,318.6%, from Rs 1 crore to Rs 131 crore PAT Margin expanded to 22.4%, up from 0.4% Cash PAT rose by 346.5%, from Rs 57 crore to Rs 254 crore Net debt to EBITDA of 4.2x as of Q1FY26, well within the targeted range of 5.5x Manoj Kumar Upadhyay, Chairperson & MD, ACME Solar Holdings, said, “We are proud to report another strong quarter, marked by robust financial performance and meaningful operational progress. The commissioning of 350 MW, including our first wind project, underscores our commitment to diversifying our clean energy portfolio. Securing our maiden standalone battery storage projects is a landmark moment - positioning us at the forefront of the energy transition as we scale solutions that enhance grid reliability and flexibility. Our continued focus on execution excellence and disciplined financial management is clearly reflected in our margin expansion, significant improvement in cash PAT, and reduced debt cost. The adoption of tariffs for majority of our under-construction portfolio and signing of key PPAs reflect the strong demand for the renewable energy solutions. We remain confident in our longterm growth trajectory and are committed to delivering sustainable value to all stakeholders.” Result PDF
Conference Call with CarTrade Tech Management and Analysts on Q1FY26 Performance and Outlook. Listen to the full earnings transcript.
Jammu & Kashmir Bank announced Q1FY26 results Net Interest Income (NII) for the quarter grew 7% YoY to Rs 1,465.43 crore, while the other income jumped 29% to Rs 250.30 crore from Rs 194.10 crore recorded last year. Return on Assets (RoA) for the quarter improved to 1.17% YoY from 1.08%, while as Net Interest Margin (NIM) for the quarter stood at 3.72% as against 3.86% recorded in Q4FY2025. Bank’s Cost to income Ratio also improved to 60.78% YoY. Operating profit witnessed a 13% YoY increase to Rs 672.84 crore from Rs 594.67 crore recorded for the corresponding period last year. Jammu & Kashmir Bank today posted a profit after tax (PAT) of Rs 484.84 crore for the April–June quarter of the current financial year (CFY), registering a 16.7% year on year (YoY) growth from Rs 415.49 crore reported in the same period last year. The Bank’s deposits rose 12% YoY to Rs 1,48,542 crore from Rs 1,32,574 crore recorded in Q1 last FY, while the net Advances grew 6.06% YoY reaching Rs 1,01,230 crore as against Rs 95,450 crore. The Bank’s CASA ratio stood at 45.71% as on June 30, 2025. MD & CEO Amitava Chatterjee said, "Despite tough situation on ground due to the Pahalgam terror attack along with its aftermath that affected business activity and credit offtake in key geographies well into June; we have been able to deliver a healthy bottom line growth of around 17%.” “The sudden decline in NIM should be viewed against the broader environment wherein repo rate cuts announced by the regulator impacted the margins”, he added. “Pertinently, the profitability for Q1 is subdued on account of impairment provision of Rs 87 crore made in this quarter towards our investment in the RRB - Jammu and Kashmir Grameen Bank, necessitated by amalgamation of Ellaquai Dehati Bank with erstwhile J&K; Grameen Bank w.e.f. 30th April 2025. Excluding this non-recurring impact, our profitability growth would be upwards of 30% YoY. This one time provision has also impacted our ROA and ROE, however on a normalised basis both metrics remain broadly in line with our expectation”, he added. “Having said that, we remain fundamentally strong, with adequate capital and liquidity buffers, and are already seeing signs of accelerating credit off-take on ground. With improving conditions on the ground, we are sure to gain growth momentum in the coming quarters”, asserted MD & CEO. MD & CEO further remarked, "Regarding business growth, we are confident in our long term strategy as we are actively diversifying and scaling up our Rest of India operations by opening more branches in strategic business centres, entering builder tie ups, and strengthening partnerships with DSAs.” “Going forward, our focus will also remain deepening relationships in core geographies through sufficient lending to agriculture, industry and youth entrepreneurship; and investing further in digital capabilities and operational efficiency." Result PDF
Pharmaceuticals company RPG Life Sciences announced Q1FY26 results RPG Lifesciences revenue recorded 2.1% YoY increase in sales (18.1% Q-o-Q growth) along with a healthy EBITDA margin of 24.1%. Profit before tax remained largely in line with previous year stood at Rs 35.4 crore in this year vs. Rs 36.0 crore in previous year Year on Year Revenue from Operations stood at Rs 168.9 crore vs. Rs 165.4 crore Ashok Nair, Managing Director, RPG Life Sciences said, “In Q1, we have sustained our sales growth momentum, reflecting the strength of our strategic execution and operational excellence. Our Domestic Formulations business continues to deliver market-beating growth, propelled by a focused transformation agenda and a customer-centric approach. We remain firmly on track to accelerate both our International Formulations and API segments, with growth driven by rapid onboarding of new customers, strategic expansion into newer markets, and launch of newer molecules that broaden our therapeutic reach.” “We are actively exploring inorganic growth opportunities across both formulations and APIs to further accelerate our growth trajectory and create lasting value for all stakeholders,” added Nair. Result PDF